BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
563 results:

  • 1. Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis.
    Liang H; Geng S; Wang Y; Fang Q; Xin Y; Li Y
    J Cell Mol Med; 2024 May; 28(9):e18315. PubMed ID: 38680032
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
    Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
    Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
    Kim YN; Chung YS; Park E; Lee ST; Lee JY
    Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.
    Rausio H; Cervera A; Heuser VD; West G; Oikkonen J; Pianfetti E; Lovino M; Ficarra E; Taimen P; Hynninen J; Lehtonen R; Hautaniemi S; Carpén O; Huhtinen K
    Neoplasia; 2024 May; 51():100987. PubMed ID: 38489912
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. AKTing on R Loops Makes for an ATRactive Target in ovarian cancer Therapy.
    Ramanarayanan V; Oberdoerffer P
    Cancer Res; 2024 Mar; 84(6):793-795. PubMed ID: 38486481
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Clonal origin and genomic diversity in Lynch syndrome-associated endometrial cancer with multiple synchronous tumors: Identification of the pathogenicity of MLH1 p.L582H.
    Takahashi K; Yachida N; Tamura R; Adachi S; Kondo S; Abé T; Umezu H; Nyuzuki H; Okuda S; Nakaoka H; Yoshihara K
    Genes Chromosomes Cancer; 2024 Mar; 63(3):e23231. PubMed ID: 38459936
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Periostin's role in uterine leiomyoma development: a mini-review on the potential periostin poses as a pharmacological intervention for uterine leiomyoma.
    Kiesler ZG; Hunter MI; Balboula AZ; Patterson AL
    Arch Gynecol Obstet; 2024 May; 309(5):1825-1831. PubMed ID: 38441600
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via pi3k-AKT pathway in advanced ovarian cancer.
    Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
    J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
    Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. VNP20009-Abvec-Igκ-MIIP suppresses ovarian cancer progression by modulating Ras/MEK/ERK signaling pathway.
    Wang Q; Tang Y; Dai A; Li T; Pei Y; Zhang Z; Hu X; Chen T; Chen Q
    Appl Microbiol Biotechnol; 2024 Feb; 108(1):218. PubMed ID: 38372808
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. β-Sitosterol targets ASS1 for Nrf2 ubiquitin-dependent degradation, inducing ROS-mediated apoptosis via the PTEN/pi3k/AKT signaling pathway in ovarian cancer.
    Wang H; Liu J; Zhang Z; Peng J; Wang Z; Yang L; Wang X; Hu S; Hong L
    Free Radic Biol Med; 2024 Mar; 214():137-157. PubMed ID: 38364944
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. MK8722 initiates early-stage autophagy while inhibiting late-stage autophagy via FASN-dependent reprogramming of lipid metabolism.
    Wang L; Zhu H; Shi Z; Chen B; Huang H; Lin G; Li J; Yu H; Xu S; Chen G; Ou R; Dai C
    Theranostics; 2024; 14(1):75-95. PubMed ID: 38164137
    [No Abstract]    [Full Text] [Related]  

  • 13. Exploration of the effect and mechanism of Scutellaria barbata D. Don in the treatment of ovarian cancer based on network pharmacology and in vitro experimental verification.
    Zhang J; Qi C; Li H; Ding C; Wang L; Wu H; Dai W; Wang C
    Medicine (Baltimore); 2023 Dec; 102(51):e36656. PubMed ID: 38134066
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/pi3k Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Activation of pi3k/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
    Zhang M; Wang J; Guo Y; Yue H; Zhang L
    J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Bailing capsule on polycystic ovary syndrome.
    Guan HR; Li B; Zhang ZH; Wu HS; He XL; Dong YJ; Su J; Lv GY; Chen SH
    BMC Complement Med Ther; 2023 Dec; 23(1):458. PubMed ID: 38102584
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Research progress on the mechanism of glycolysis in ovarian cancer.
    Li C; Liu FY; Shen Y; Tian Y; Han FJ
    Front Immunol; 2023; 14():1284853. PubMed ID: 38090580
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in ovarian cancer.
    Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
    Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Genomic and Molecular Characteristics of ovarian Carcinosarcoma.
    Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
    Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
    Sohel M
    Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 29.